Upon DNA damage, phosphorylation and nuclear translocation of wild-type p53 tumor suppressor protein signals its functional activation. However, very little is known about phosphorylation and localization of mutant p53. We found that mutant p53 protein in UV-induced murine primary skin tumors and cultured cell lines was constitutively phosphorylated at serine 15 residue and localized in the cell's nuclei. To investigate the mechanism of constitutive phosphorylation of mutant p53, we tested the involvement of a wide range of protein kinases and found that ERK1/2 mitogen-activated protein kinase was physically associated with mutant p53 in the nucleus. Addition of active recombinant ERK2 kinase protein in vitro to immunoprecipitated mutant p53 resulted in increased phosphorylation at serine 15. Furthermore, ERK1/2 activity was higher in tumor cells than normal cells, suggesting that phosphorylation of mutant p53 at serine 15 depends on the level of ERK1/2 activation. Interestingly, accumulation of mutant p53 in tumor cells was paralleled by low levels of Murine Double Minute 2 protein (MDM2) expression. However, when MDM2 was overexpressed, the fraction of mutant p53 that was phosphorylated at serine 15 resisted degradation, whereas the level of total p53 decreased, suggesting that phosphorylation at serine 15 and downregulation of MDM2 protein may both contribute to stabilization of mutant p53 in tumor cells.
Introduction
The tumor suppressor protein p53 functions as a latent, short-lived transcription factor (Harris, 1993) . Stabilization and functional activation of p53 occurs in response to DNA damage via a complex mechanism that includes protein polyphosphorylation at N-and C-terminal residues (Steegenga et al., 1996) and nuclear retention of the oligomerized protein (Pietenpol et al., 1994) . Stabilized p53 transcriptionally activates genes encoding proteins involved in cell cycle arrest, DNA repair, and/ or apoptosis, and represses transcriptional activation of growth-promoting genes (Ko and Prives, 1996; Levine, 1997) . The N terminus of p53 contains several serine residues situated close to or within the binding sites of transcriptional coactivator p300/CBP, TATA-binding protein-associated factors, and Murine Double Minute 2 protein (MDM2 1 ) (Lu and Thut et al., 1995; Haupt et al., 1997; Van Orden et al., 1999; De Guzman et al., 2000) . Phosphorylation of one of the key residues, serine 15, has been shown to coordinate polyphosphorylation of p53 (Kapoor et al., 2000) and stabilize the protein through disruption of MDM2 binding (Shieh et al., 1997) . Phosphorylation of serine 15 also prevents p53 from being exported from the nucleus and stimulates p53 transcriptional activity through the increased association with p300 coactivator (Lambert et al., 1998; Dumaz and Meek, 1999; Zhang and Xiong, 2001) .
Several protein kinases have been shown to phosphorylate wild-type p53 at serine 15. Early in vitro studies indicated that serine 15 is a substrate for phosphorylation by a member of phosphatidyl-inositol-3 0 -kinase family (PI-3 K), DNA-dependent protein kinase (DNA-PK) (Lees-Miller et al., 1992) , although the ability of DNA-PK to phosphorylate p53 in vivo has been recently disproved Burma et al., 1999) . Evidence exists for the involvement of the PI-3 family kinases, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia related (ATR) in phosphorylation of the serine 15 in response to g or UV irradiation (Banin et al., 1998; Tibbetts et al., 1999) . Recently, mitogen-activated protein kinases (MAPK) p38 and ERK1/2 have been implicated in phosphorylation of human p53 at serine 15 in response to UV irradiation, treatment with cisplatin, and resveratrol (Persons et al., 2000; She et al., 2000 She et al., , 2001 .
Normal functions of wild-type p53 are abrogated by mutations in this gene. Several studies have shown that the p53 gene is a common target for carcinogen-specific mutations and that more than 50% of human cancers contain point mutations (Hollstein et al., 1994) . In particular, mutations in the p53 gene induced by UV irradiation are causally implicated in the development of nonmelanoma skin cancers (Kanjilal et al., 1993; Brash et al., 1996) . The frequency of UV-signature mutations, mainly characterized by C-T or CC-TT transitions at dipyrimidine sites, reaches 50-80% in human basal and squamous cell carcinomas and 100% in murine UVinduced skin tumors (Kanjilal et al., 1993; Brash et al., 1996) . It is generally accepted that loss of p53 functions occurs as a result of transdominant suppression of wildtype p53, leading to impairment of wild-type p53-mediated development and differentiation, apoptosis, growth arrest, and other physiological processes (Gottlieb et al., 1994; Aloni-Grinstein et al., 1995) . However, an increasing body of work indicates that certain p53 mutants exert oncogenic features due to acquisition of novel functions that confer proliferative advantage to cells sustaining genetic damage (Sigal and Rotter, 2000) . Certain mutants of p53 have been shown to promote cell growth (Dittmer et al., 1993) , transactivate promoters of epidermal growth factor receptor and basic fibroblast growth factor proteins (Ueba et al., 1994; Ludes-Meyers et al., 1996; Sheikh et al., 1997) , and potentiate the expression of vascular endothelial growth factor (Kieser et al., 1994) . Although tumor-derived mutants are generally defective in binding to promoters containing wild-type p53 response elements (Ko and Prives, 1996) , they are nonetheless capable of binding to nonspecific DNA sequences (Koga and Deppert, 2000) . Structural requirements for acquiring the 'gain of function' phenotype by mutant p53 proteins consist of retention of the intact transactivation and nonsequence-specific DNA-binding domains (Lin et al., 1995; Lanyi et al., 1998) as well as p53 oligomerization (Lanyi et al., 1998) . However, little is known about the phosphorylation of mutant p53, which in analogy to wild-type p53 may be involved in stabilization of mutant protein and/or its transcriptional activity. This led us to hypothesize that mutant p53 may be phosphorylated at critical N-terminal residues in tumors containing specific mutations.
We have found that mutant p53 expressed in UVinduced primary mouse skin tumors and cell lines established from primary tumors is constitutively phosphorylated at serine 15 and accumulates in cell nuclei. Constitutive phosphorylation of mutant p53 at serine 15 was mediated by ERK1/2 MAP kinase, which was physically bound to mutant p53 in the nucleus. Only a portion of mutant p53 was phosphorylated in tumor cells. Nonphosphorylated p53 was stabilized when MDM2 expression was low. However, when MDM2 was overexpressed in tumor cells, nonphosphorylated p53 underwent degradation, whereas serine-15 phosphorylated p53 did not.
Results
p53 gene is mutated in UV-induced primary mouse skin tumors and tumor cell lines Analysis of p53 exons 4-8, encoding the sequencespecific DNA-binding domain of the p53 protein, identified CC-to-TT, C-to-T, or A-to-G transitions at codons 154-155, 175-176, 270 or 283 in all the primary tumors and cell lines (Table 1 ). Mutations at these 'hot spot' codons are characteristic of UV-induced mutagenesis (Kanjilal et al., 1993; Brash et al., 1996) . In addition, analysis of exon 2, encoding the N terminus of the protein, and exons 9 and 10, encoding the C-terminal nuclear export signal region of p53 (Stommel et al., 1999) , did not reveal mutations in any of the primary tumors or cell lines.
Mutant p53 is constitutively phosphorylated at serine 15 and localizes in the cell's nuclei in UV-induced mouse tumors
Immunoblotting of whole-cell lysates showed that tumor cells expressed high amounts of stabilized mutant p53, which was constitutively phosphorylated at serine 15 ( Figure 1a ). In contrast, p53 protein was undetectable in normal 10T1/2 fibroblasts or JB6 epidermal cells. It is interesting that the difference in the level of total p53 protein between various tumor cell lines correlated with the difference in levels of p53 phosphorylation at serine 15. This suggests either that the same portion of mutant p53 is phosphorylated at serine 15 in any given tumor cell line or that To determine whether mutant p53 was also constitutively phosphorylated in UV-induced primary tumors, we analysed paraffin-embedded tissues from five tumors known to contain missense point mutations (Table 1) for expression of p-Ser15-p53 protein. The results indicated that all the five tumors expressed high levels of total p53 protein, and all of them stained positive with anti-p-Ser15-p53 antibody. Representative immunohistochemical data for a fibrosarcoma shown in Figure 2b revealed intense nuclear staining with anti-p53 antibody (left panel). Strong immunostaining with anti-p-Ser15-p53 antibody was observed exclusively in the nuclei (right panel). Thus, data from both tumor cell lines and primary tumors indicate that constitutive phosphorylation of mutant p53 at serine 15 is a common feature of UV-induced mouse tumors.
ERK1/2 MAPK is constitutively activated and binds to mutant p53 in UV-induced tumor cells
To investigate the mechanism of constitutive phosphorylation of mutant p53 at serine 15, we first compared the levels of MAPK expression and phosphorylation in normal and UV-induced tumor cell lines. The results, shown in Figure 3a , indicated that ERK1/2 proteins were expressed at similar levels in all the normal and tumor cell lines, but the degree of ERK1/2 phosphorylation was generally higher in tumor cells, suggesting that ERK1/2 kinase is constitutively activated in tumor cells. Furthermore, in tumor cell lines 2237 and 96.1, which consistently showed the highest levels of serine 15 phosphorylation, ERK1/2 activity (measured by an in vitro kinase activity assay) was notably elevated compared with that seen in normal 10T1/2 cells ( Figure 3b ). Other members of the MAPK family, JNK and p38 MAPK, which have been previously shown to phosphorylate wild-type p53 at threonine 81, serine 20, and serine 15 in stress-related conditions (She et al., 2000 (She et al., , 2002 Buschmann et al., 2001) , were expressed at similar levels, but they existed in nonphosphorylated form in both normal and tumor cell lines (data not shown).
To test whether ERK1/2 can phosphorylate mutant p53 at Serine 15 directly, we performed an in vitro kinase assay using activated recombinant ERK2 protein and Figure 3c ). These results indicate that mutant p53 is a substrate for phosphorylation at serine 15 by ERK2 kinase. We further investigated the possible formation of a complex between ERK1/2 protein and mutant p53. Immunoprecipitation with anti-p-ERK1/2 antibody and subsequent immunoblotting with anti-p53 or anti-pSer15-p53 showed that ERK1/2 protein is associated with mutant p53 in 96.1 and 2237 cell lines (Figure 4a ). This observation was confirmed by reverse immunoprecipitation with anti-p53 antibody, which co-precipitated p-ERK1/2 proteins (Figure 4a ).
Activated MAP kinase translocates into the nucleus. Indeed, immunocytochemical staining revealed abundant nuclear localization of phosphorylated ERK1/2 proteins in 2237 cells (Figure 4b ). The detection of a complex between ERK1/2 and mutant p53, their nuclear localization, as well as the ability of active ERK2 kinase to phosphorylate mutant p53 in vitro suggests that constitutive phosphorylation of mutant p53 at serine 15 is mediated by ERK1/2 MAP kinase. In contrast, we were unable to detect any physical association between ATM, c-JNK, or p38 proteins and mutant p53 in 2237 cells (data not shown).
Role of phosphorylation of serine 15 in stabilization of mutant p53 protein
To assess the role of phosphorylation of serine 15 site in stabilization of mutant p53, we first sought to determine whether all p53 protein is phosphorylated constitutively. Figure 5a shows that UVB irradiation (75 J/m 2 ) caused significant increase in phosphorylation of mutant p53 at serine 15. However, the levels of total p53 remained unchanged, suggesting that not all serine 15 residues of mutant p53 are phosphorylated constitutively. Interestingly, increased phosphorylation of mutant p53 at serine 15 following UVB irradiation correlated with increased levels of phosphorylated ERK1/2 kinase (Figure 5a ), suggesting further that ERK1/2 kinase may be involved Figure 3 (a) Expression of total ERK1/2 proteins and the level of ERK1/2 phosphorylation in tumor cell lines. The blot was first probed with antibody against total ERK1/2, then stripped and reprobed using anti-p-ERK1/2 antibody, then stripped and reprobed again using antibody against actin. (b) Kinase activity associated with ERK1/2 is higher in tumor cell lines 96.1 and 2237 than in normal 10T1/2 fibroblasts. Cell lysates were immunoprecipitated with p-ERK1/2 monoclonal antibody and subjected to a kinase assay using Elk-1 protein as the substrate for phosphorylation. (c) Activated recombinant ERK2 kinase protein phosphorylates mutant p53 in vitro. Mutant p53 was precipitated from 2240 cells and subjected to kinase reaction using active recombinant ERK2. Higher level of phosphorylation at serine 15 is seen after kinase reaction as detected by immunoblotting using anti-p-Ser15-p53 antibodies. No protein extract was added in a negative control Chromatin was visualized with propidium iodide (red). Overlaying the two images reveals a large portion of p-ERK1/2 with nuclear localization in phosphorylation of mutant p53 at serine 15. Since all the tumor cell lines tested expressed very low levels of MDM2 protein (data not shown), these results suggest that nonphosphorylated p53 is stable under conditions of low MDM2 expression.
To further investigate whether mutant p53 in tumor cells was stabilized because of diminished production of MDM2, we induced the expression of MDM2 in 2237 tumor cells by transfection with a pCMVKimdm2-neo vector and then determined whether expression of mutant p53 was affected. The results, shown in Figure 5b , indicated that increased expression of MDM2 resulted in decreased expression of total p53 protein. However, the level of p-Ser15-p53 remained unchanged in cells overexpressing MDM2. These results suggest that analogous to wild-type p53, mutant p53 His270Cis is also susceptible to MDM2-mediated degradation unless it is phosphorylated at serine 15.
We also performed immunofluorescence staining to determine whether nuclear localization of mutant p53 was affected in 2237 cells overexpressing MDM2. The results indicated that p53 relocalized into the bright subnuclear foci (Figure 6a ). These zones colocalized with the areas of condensed chromatin visualized by propidium iodide (Figure 6a ). Relocalization was paralleled by an overall decrease in diffuse p53-associated fluorescence in the nuclei of these cells. Double staining with anti-p53 and anti-p-Ser15-p53 antibodies showed no concomitant relocalization of p53 phosphorylated at serine 15 (Figure 6b ). These observations are in concordance with Western blot data ( Figure 5b ) and suggest that phosphorylation of mutant p53 at serine 15 remains unaffected by MDM2 overexpression. Further, MDM2 localized diffusely in the nucleus and cytoplasm and, unlike relocalized mutant p53, it did not accumulate in subnuclear structures (Figure 6c) . Finally, to distinguish areas of p53 relocalization, we performed double staining with antip53 antibody and antibody against p19 ARF protein (used as a marker for nucleoli (Zhang and Xiong, 2001) ). Results, shown in Figure 6d , identified areas of mutant p53 relocalization as nucleoli in cells overexpressing MDM2.
Discussion
Using UV-induced primary skin tumors and cell lines, we demonstrated that mutant p53 protein is constitutively phosphorylated at one of the key N-terminus residues, serine 15 (Figure 1) . Constitutive phosphorylation of mutant p53 was not unique to UV-induced mouse skin tumors, because mutant p53 (Arg280Lys, Leu194Phe, and Arg273His) expressed in two human breast and one human pancreatic cancer cell lines was also constitutively phosphorylated at human serine 15 (data not shown). In addition, mutant p53 was found to be constitutively phosphorylated at the C-terminal serine 389 residue in both mouse tumors and tumor cell lines (data not shown). In contrast, very low levels of phosphorylation at serine 20 residue were detected in two out of seven cell lines (Figure 1b) . This residue is situated in the domain of p53 interaction with MDM2 and is known to affect stability of the wild-type p53 (Chehab et al., 1999; Unger et al., 1999a) . Nonetheless, these results support recent observations of increased phosphorylation of mutant p53 in human tumors and suggest that constitutive phosphorylation of mutant p53 is a general phenomenon in tumor cells independent of both the inducing carcinogen and the tumor type.
To follow up on this initial observation, we investigated the localization of phosphorylated mutant p53, the mechanism of constitutive phosphorylation of mutant p53 at serine 15, and its possible role in stabilization of protein. In all tumor cell lines and primary skin tumors tested, mutant p53 phosphorylated at serine 15 was localized in the nucleus (Figure 2) . Given the high amounts of p-Ser15-p53 localized in the nucleus, we can speculate that if phosphorylation of Nterminal residues serves to facilitate the transcriptional function of mutant p53, as has been shown for the wildtype protein (Lambert et al., 1998; Dumaz and Meek, 1999; Unger et al., 1999b; Zhang and Xiong, 2001 ), the effect of activity of mutant p53 may be considerable.
In order to examine the mechanism of constitutive phosphorylation of mutant p53 at serine 15, we hypothesized that it should be associated with constitutive activation of some protein kinases. We found that levels of ERK1/2 phosphorylation were generally higher in tumor cells than in normal cells (Figure 3a) . In addition, kinase activity assay revealed much higher activity of ERKs in tumor cell lines expressing highest amounts of phosphorylated p53 (Figure 3b) . Furthermore, addition of active recombinant ERK2 kinase in vitro to immunoprecipitated mutant p53 resulted in increased phosphorylation at serine-15 residue (Figure 3c) . These results strongly suggest that phosphorylation of mutant p53 at serine 15 is mediated by ERK1/2 MAP kinase. Indeed, immunoprecipitation experiments showed that mutant p53 was physically bound to phosphorylated ERK1/2 proteins (Figure 4a) . The physical association between ERK1/2 and wild-type p53, paralleled by phosphorylation of p53 at serine 15, has been previously shown to occur in response to UV irradiation, as well as treatment with cisplatin and resveratrol (Persons et al., 2000; She et al., 2000 She et al., , 2001 . Evidently, the p53
Arg270Cys mutant retains the ability to form a complex with ERK1/2. ERK1/2 involvement in p53 phosphorylation was further supported by the findings that large amounts of p-ERK1/2 localized in the cell's nuclei (Figure 4b) , and that UV-induced increase in p53 phosphorylation at serine 15 was accompanied by simultaneous increase in ERK1/2 phosphorylation (Figure 5a) .
Initial results suggested that levels of phosphorylation at serine 15 correlated with the total levels of mutant p53, possibly implicating p-Ser15 in stabilization of mutant p53. However, we found that only a portion of p53 was constitutively phosphorylated. This observation is in agreement with that made by Nagata et al. (1999) , who found that phosphorylation of transfected mutant p53
Arg248Trp at serine 15 occurs rather inefficiently and concluded that it is therefore dispensable for the stabilization of this mutant protein.
The absence of feedback regulation by MDM2 is believed to cause stabilization of mutant p53 (Blagosklonny, 1997; Levine, 1997; Sigal and Rotter, 2000) . Indeed, skin tumor cells expressed very low levels of MDM2, suggesting that nonphosphorylated mutant p53 is stable under conditions of diminished MDM2 production. Taking into account that p53 mutants remain susceptible to nuclear export (Zhang and Xiong, 2001 ) and MDM2-mediated degradation (Buschmann et al., 2000; Brown et al., 2001) and that overexpression of MDM2 can repress the accumulation of mutant p53 in tumor-derived cells (Haupt et al., 1997) , we transfected 2237 cells with MDM2 expression vector to monitor changes in total and phosphorylated mutant p53. Overexpression of MDM2 was found to destabilize mutant p53 without affecting the levels of p-Ser15-p53 (Figure 5b ). A decrease in the level of nonphosphorylated p53 suggests that phosphorylation at serine 15 prevents degradation of mutant p53 by MDM2. It is interesting that in cells overexpressing MDM2, nonphosphorylated mutant p53 relocalized into the nucleoli (Figure 6 ). This relocalization did not require similar accumulation of MDM2. It is possible that mutant p53, once ubiquitinated by MDM2, passes through the nucleoli on its way out of the nucleus. Furthermore, detection of high amounts of nucleolar p19 ARF suggests that this protein may also protect nucleolar mutant p53 from nuclear export (Tao and Levine, 1999; Buschmann et al., 2000) . Finally, as in wild-type p53, phosphorylation at serine 15 might block N-terminal nuclear export signal and prevent nuclear export of mutant p53 (Zhang and Xiong, 2001) . Further experiments are needed to distinguish between these possibilities.
In summary, both murine and human tumor-derived p53 mutants were found to be constitutively phosphorylated at serine 15 independently of the type of mutation. The detection of a complex between ERK1/2 and mutant p53, their nuclear localization, as well as the ability of active ERK2 kinase to phosphorylate mutant p53 in vitro suggests that constitutive phosphorylation of mutant p53 at serine 15 is mediated by ERK1/2 MAP kinase. However, only a portion of mutant p53 was constitutively phosphorylated at serine 15. Overexpression of MDM2 caused decrease in the amount of nonphosphorylated mutant p53 without affecting the amount of serine-15 phosphorylated p53. Thus, phosphorylation at serine 15 and downregulation of MDM2 expression in UV-induced tumor cells both contribute to stabilization of mutant p53 protein.
Materials and methods

Tumors and cell lines
Primary skin tumors were induced in female C3 H mice by chronic UVB irradiation as described previously (Ananthaswamy et al., 1997) . The cell lines 96.1, 97.4, 98.1.1, 98.1.25, 1463, 2237, and 2240 were established from the UVB-induced primary skin tumors (Pierceall et al., 1992; Kanjilal et al., 1993) . Normal embryo fibroblasts from C3 H mice (10T1/2) and JB6 epidermal cells derived from BALB/c mice were obtained from the American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in Dulbecco's modified Eagle's medium (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Hyclone Laboratories Inc., Logan, UT, USA) in an atmosphere of 5% CO 2 .
Reagents
Mouse monoclonal IgG against MDM2 (SMP14) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); mouse monoclonal IgG against p53 (Ab-1) and against p21
Waf1/Cip1 (Waf-4) were from Oncogene Research Products (Boston, MA, USA); CM5 rabbit polyclonal IgG against p53 were from Novocastra (Newcastle, UK). Phospho-specific rabbit polyclonal IgG against p53 phosphorylated at serine 15 (p-Ser15-p53), serines 389 or 20, mouse monoclonal IgG against SAPK/JNK, rabbit polyclonal IgG against p38 MAPK, rabbit polyclonal anti-ERK1/2, rabbit polyclonal anti-p-SAPK/JNK (Thr183/Tyr185), anti-p-p38 (Thr180/ Tyr182), and anti-p-ERK1/2 (Thr202/Tyr204) IgG, and the ERK1/2 kinase assay kit were all obtained from Cell Signaling Technology (Beverly, MA, USA). Active recombinant ERK2 kinase was from New England Biolabs, Beverly, MA, USA.
p53 mutations
Exons 2-11 of p53 gene were amplified by PCR and sequenced as described before (Kanjilal et al., 1993; Ananthaswamy et al., 1998) .
Generation of stable MDM2 transfectants
The pCMVKimdm2-neo expression vector was a gift from Dr Guillermina Lozano (The University of Texas MD Anderson Cancer Center, Houston, TX, USA); this plasmid contains full-length mouse mdm2 cDNA placed downstream of an early cytomegalovirus promoter and neomycin resistance gene. For stable transfection, cells were transfected with 5 mg plasmid DNA using transfection reagent (Transfast, Promega Corporation, Madison, WI, USA). Control samples were transfected with 5 mg pCMVKi-neo plasmid lacking mdm2 cDNA. Stable transfectants were selected using culture medium supplemented with 0.2 mg/ml G418 (GIBCO BRL-Invitrogen, Carlsbad, CA, USA). Expression of MDM2 protein in G418-resistant clones was verified by Western blotting. Four clones transfected with an empty vector and four clones found to overexpress MDM2 protein were combined to avoid clonal variation during analysis of the level of mutant p53 protein.
Western blot analysis
Cells were harvested at 80% confluency and lysed on ice for 30 min in lysis buffer (20 mm Tris, pH 7.5; 150 mm NaCl; 1% Triton X-100; 1 mm EDTA; 1 mm EGTA; 2.5 mm sodium pyrophosphate; 1 mm b-glycerolphosphate; 1 mm sodium orthovanidate; and 1 mg/ml leupeptin) supplemented with a Complete Mini tablet containing additional protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA). Protein extracts were resolved by 8-12% SDS-PAGE, electrophoretically transferred to a nitrocellulose membrane, blocked with 3% milk, probed with antibodies, and developed, using a chemiluminescence detection kit (NEN Life Science Products, Boston, MA, USA).
Coimmunoprecipitation assay
Cell lysates (200 mg) were precleared with protein A/G-agarose beads, incubated with immunoprecipitation antibodies (1 mg) in a total volume of 500 ml for 4-8 h, followed by the addition of 50 ml of protein A/G-agarose beads for 2 h. After four washes, proteins were separated by boiling in nonreducing 3 Â sample buffer (150 mm Tris-HCl, pH 6.8; 6% SDS; 0.3% bromophenol blue; and 30% glycerol), microcentrifuged, and analysed by Western blotting.
ERK kinase activity assay
Kinase activity assay of ERK1/2 endogenous proteins was carried out using a Cell Signaling Technology kit according to the manufacturer's recommendations. Briefly, p-ERK1/2 proteins were immunoprecipitated from 200 mg of cell lysates using immobilized p-ERK1/2 monoclonal antibody. After overnight incubation, the beads were washed twice with lysis buffer, and twice with kinase buffer (25 mm Tris, pH 7.5; 5 mm b-glycerolphosphate; 2 mm DTT; 0.1 mm Na 3 VO 4 ; and 10 mm MgCl 2 ). The kinase reaction was carried out in the presence of 200 mm ATP at 301C for 30 min using 2 mg of Elk-1 protein as a substrate for ERKs. Phosphorylated Elk-1 protein was detected by immunoblotting using phospho-specific antibodies.
In vitro phosphorylation of mutant p53
Phosphorylation of immunoprecipitated mutant p53 from 2240 cells by active recombinant ERK2 kinase was carried out at 301C for 30 min in the presence of the kinase buffer with 200 mm ATP. The p53 protein phosphorylated at Serine 15 was detected by immunoblotting using anti-p-Ser15-p53 antibodies.
Immunocytochemistry
Cells were grown on poly-lysine-treated (Fisher Scientific, Pittsburgh, PA, USA) chamber slides, fixed for 5 min with 4% paraformaldehyde, permeabilized with 0.05% Triton X-100 in PBS for 5 min, and blocked with PBS þ 5% normal horse serum þ 1% normal goat serum for 1 h. Primary antibodies were diluted in a blocking buffer and incubated overnight at 41C. Biotinylated secondary antibodies were added for 2 h, followed by addition of fluorescein-labeled avidin D (1 : 2000) in sodium biocarbonate solution (0.1 m NaHCO 2 and 0.15 m NaCl; pH 8.5). Propidium iodide (0.01 mg/ml in PBS) was added to visualize chromatin. For simultaneous staining of two proteins, cells were coincubated overnight with Ab-1 and p-Ser15-p53, or with CM5 and SMP14, or with Ab-1 and antip19 ARF antibodies (p19 ARF was used as a marker for nucleoli in 2237 cells because of the absence of stable antibodies against murine nucleolar proteins). Biotinylated goat anti-rabbit antibody (1 : 1000) and FITC-labeled goat anti-mouse antibody (1 : 1000) were added for 2 h. Cells were washed and incubated with Texas Red-labeled avidin D (1 : 2000) for 2 h. ProLong Antifade reagent (Molecular Probes, Eugene, OR, USA) was added to slides before mounting.
Immunohistochemistry
Immunohistochemical staining of paraffin-embedded tissue sections was performed as described earlier (Hill et al., 1999; Ouhtit et al., 2000) . Ab-1 monoclonal antibody (1 : 100) or anti-p-Ser15-p53 antibody (1 : 500) were used to detect total and phosphorylated p53.
